Transformation by HrasG12V is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition
Open Access
- 18 November 2013
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 33 (47) , 5442-5449
Abstract
RAS-driven malignancies remain a major therapeutic challenge. The two-stage 7,12-dimethylbenz(a)anthracene (DMBA)/12-o-tetradecanoylphorbol-13-acetate (TPA) model of mouse skin carcinogenesis has been used to study mechanisms of epithelial tumor development by oncogenic Hras. We used mice with an HrasG12V knock-in allele to elucidate the early events after Hras activation, and to evaluate the therapeutic effectiveness of farnesyltransferase inhibition (FTI). Treatment of Caggs-Cre/FR-HrasG12V mice with TPA alone was sufficient to trigger papilloma development with a shorter latency and an ∼10-fold greater tumor burden than DMBA/TPA-treated WT-controls. HrasG12V allele copy number was increased in all papillomas induced by TPA. DMBA/TPA treatment of HrasG12V knock-in mice induced an even greater incidence of papillomas, which either harbored HrasG12V amplification or developed an HrasQ61L mutation in the second allele. Laser-capture microdissection of normal skin, hyperplastic skin and papillomas showed that amplification occurred only at the papilloma stage. HRAS-mutant allelic imbalance was also observed in human cancer cell lines, consistent with a requirement for augmented oncogenic HRAS signaling for tumor development. The FTI SCH66336 blocks HRAS farnesylation and delocalizes it from the plasma membrane. NRAS and KRAS are not affected as they are alternatively prenylated. When tested in lines harboring HRAS, NRAS or KRAS mutations, SCH66336 delocalized, inhibited signaling and preferentially inhibited growth only of HRAS-mutant lines. Treatment with SCH66336 also induced near-complete regression of papillomas of TPA-treated HrasG12V knock-in mice. These data suggest that farnesyl transferase inhibitors should be reevaluated as targeted agents for human HRAS-driven cancers, such as those of bladder, thyroid and other epithelial lineages.Keywords
This publication has 47 references indexed in Scilit:
- SomaticRASMutations Occur in a Large Proportion of SporadicRET-Negative Medullary Thyroid Carcinomas and Extend to a Previously Unidentified ExonThe Journal of Clinical Endocrinology & Metabolism, 2012
- Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson–Gilford progeria syndromeProceedings of the National Academy of Sciences, 2012
- Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesisNature Communications, 2012
- Regulating the regulator: post-translational modification of RASNature Reviews Molecular Cell Biology, 2011
- RAS oncogenes: weaving a tumorigenic webNature Reviews Cancer, 2011
- Functional Specificity of Ras Isoforms: So Similar but So DifferentGenes & Cancer, 2011
- Endogenous expression of Hras G12V induces developmental defects and neoplasms with copy number imbalances of the oncogeneProceedings of the National Academy of Sciences, 2009
- A mouse model for Costello syndrome reveals an Ang II–mediated hypertensive conditionJournal of Clinical Investigation, 2008
- Tumour maintenance is mediated by eNOSNature, 2008
- While K-ras Is Essential for MouseDevelopment, Expression of the K-ras 4A Splice VariantIsDispensableMolecular and Cellular Biology, 2003